Pharma Mar's oncology segment is dedicated to the discovery, development, and commercialization of innovative anti-cancer therapies derived from marine sources. This segment focuses on addressing unmet medical needs in various cancer types, including soft tissue sarcomas, ovarian cancer, and small cell lung cancer. Key activities include preclinical research, clinical trials, and regulatory submissions for novel drug candidates. The company leverages its expertise in marine biotechnology to identify and develop compounds with unique mechanisms of action. The oncology segment is driven by a commitment to improving patient outcomes and quality of life through targeted therapies and personalized medicine approaches. Strategic partnerships and collaborations play a crucial role in expanding the reach and impact of Pharma Mar's oncology portfolio.

The diagnostics segment of Pharma Mar focuses on the development and marketing of diagnostic kits for various diseases. This segment plays a crucial role in early detection, disease monitoring, and personalized treatment strategies. Research and development efforts are directed towards creating highly sensitive and specific diagnostic tools that can improve patient outcomes. The company utilizes advanced technologies such as molecular diagnostics and immunoassays to develop innovative diagnostic solutions. The diagnostics segment is committed to providing healthcare professionals with reliable and accurate tools for informed decision-making. By leveraging its expertise in biotechnology and diagnostics, Pharma Mar aims to contribute to the advancement of precision medicine and improve patient care.

Pharma Mar's RNA interference (RNAi) segment is dedicated to developing drugs with therapeutic activity based on reducing or silencing gene expression. This innovative approach targets the root cause of diseases by selectively inhibiting the production of disease-causing proteins. Research and development efforts focus on identifying and validating RNAi targets, designing effective RNAi therapeutics, and optimizing delivery methods. The company utilizes advanced technologies such as siRNA and miRNA to develop targeted therapies for a wide range of diseases. The RNAi segment is driven by a commitment to developing transformative medicines that can address unmet medical needs and improve patient outcomes. Strategic partnerships and collaborations play a crucial role in advancing the development and commercialization of RNAi therapeutics.